Depression
300 million People Globally Affected By Depression
$60 Billion Market in 2020
CANCER
10 million People Globally Die of Cancer Every Year
$100 Billion Market in 2020
Viral Infections
1 Billion + People Globally Get Viral Infections every year
$59.9 Billion Market in 2020
Obesity
2.7 Billion People are Obese, Nearly 30% of the worlds population
$2 Trillion Market in 2018
Inflammation
350 Million People Globally are affected by Arthritis
and Joint Diseases
$93.88 Billion Market in 2019
Aion Therapeutic combines healing compounds from medical cannabis and medicinal mushrooms to create combinatorial therapeutic pharmaceuticals, nutraceuticals, and cosmeceuticals.
CUTTING EDGE RESEARCH, WORLDWIDE PRODUCTION
Aion Therapeutic has strategically positioned itself in Jamaica where medicinal mushrooms including “magic” mushrooms containing psilocybin have never been made illegal and where medical cannabis is federally legal and regulated. In partnership with our medical cannabis licensed partner, Apollon Formularies Jamaica, Ltd. we are able to perform this type of combinatorial research and development, treat patients, and commercialize our product lines in a fully federally legal environment. In fact, in one of the very few places on earth where it is legal to operate and create these medical cannabis and medicinal mushroom combinatorial products which may legally include both psilocybin and THC.
LEVERAGING ARTIFICIAL INTELLIGENCE FOR OUR THERAPEUTIC DISCOVERIES
Aion Therapeutic Processes and Analyzes Plant & Mushroom Genetics, Phenotypes and
Biochemistry With Proprietary Artificial Intelligence Techniques.
We will utilize Artificial Intelligence Techniques
to create disease specific patentable medical cannabis/mushroom formulation treatments to create Personalized Medicine
PATENT PORTFOLIO OF FORUMULATION THERAPEUTICS
1. Compositions and Methods for Treatment of Cancers
2. Compositions and Methods for Treatment of Psychoses and Psychotic Disorders
3. Antiviral Compositions and Methods for Their Use
4. Compositions and Methods for Treatment of Inflammation
5. Compositions and Methods for Promoting Weight Loss and For Treatment of Obesity
Aion International Center
for Psychedelic Psychiatry
Aion Therapeutic Inc. announced on February 17th 2021 the opening of the Aion International Center for Psychedelic Psychiatry in Jamaica. The Center will initially specialize in the use of psilocybin for the treatment of addiction (tobacco, alcohol and other drug misuse), depression and anxiety associated with life-threatening illnesses, and treatment-resistant depression. In addition, the Center will be studying the effectiveness of psilocybin as a new therapy for opioid addiction, Alzheimer's disease, post-traumatic stress disorder (PTSD), and anorexia nervosa.
The Medical Director of the Aion International Center for Psychedelic Psychiatry is Winston De La Haye, M.D., M.P.H, D.M., I.C.A.P. Dr. De La Haye is Deputy Dean in the Faculty of Medical Sciences, The University if the West Indies (UWI), Mona, Jamaica and a Consultant General and Addiction Psychiatrist at the University Hospital of the West Indies (UHWI). He completed his MD (Cum Laude) at the University of Pecs in Hungary, his Postgraduate Degree in Psychiatry at the UWI, his Masters in Public Health (Cum Laude) and a Fulbright Fellowship in Substance Abuse at the Johns Hopkins University (JHU). He is an Internationally Certified Addiction Professional and a Global Master Trainer of Trainers in the Treatment of Substance Use Disorders.
Dr. De La Haye is a Past Chief Medical Officer in the Ministry of Health and Wellness in Jamaica, Member of the Medical Council of Jamaica, Member of the International Society for Substance Use Professionals (ISSUP), Past President of the Medical Association of Jamaica, Past President of the Jamaica Psychiatric Association, Past President of the Jamaica Fulbright Alumni Association, Past Chairman of the Bellevue Hospital Board of Management, and Past Deputy Chairman of the National Council on Drug Abuse in Jamaica.
Dr. De La Haye established the Medicinal Cannabis Unit in the Ministry of Health and Wellness in July 2017, supervising the registration of over 80 medicinal cannabis products in Jamaica. He is a former Captain in the Jamaica Defense Force.
Dr De La Haye stated - "We need all available and effective products for the treatment of patients with mental illness. Psychedelic Psychiatry has the potential to change the lives of millions of patients, reducing their disability and improving their quality of life." Dr. De La Haye continued “As a Johns Hopkins Alumnus, it is our intention to follow the best treatment protocols like those being established at Johns Hopkins Center for Psychedelic and Consciousness Research’
Aion International Center for Psychedelic Psychiatry, in addition to treating patients, looks forward to collaborating with The UWI and other Tertiary Institutions in Jamaica in the research and development of cutting edge, effective and safe products for treating patients with mental illness. We also recognize the importance of regulating the Psychedelic Industry and look forward to working closely with the MOHW in Jamaica as they move towards setting up this very important regulatory body.
The offices of Aion International Center for Psychedelic Psychiatry will soon be opened for seeing both Jamaican and international patients. We are planning a grand opening celebration in the very near future. The date will be based on the lifting of the COVID-19 restrictions.
Press Releases
Aion Therapeutic Opening the First International Treatment Center for Psychedelic Psychiatry in Jamaica; Hires Leading Psychiatrist as Medical Director
2/23/2021
Aion Therapeutic Announces Closing of Non-Brokered Private Placement
12/23/2020
Aion Therapeutic Amends Convertible Debentures
10/31/2020
Aion Therapeutic Names James W.G. Thompson, Ph.D. as President
10/21/2020
Aion Therapeutic, Inc. Announces the Appointment of Dr. Herbert Fritsche, Former Professor of Laboratory Medicine and Chief of the Clinical Chemistry Section at the University of Texas, MD Anderson Cancer Center in Houston, Texas as Chief Science Officer 9/10/2020